IR Inquiry

EDGC strives to be transparent and reliable company.

'Dementia will be treated preemptively': EDGC co-CEO

Date : 20-11-30 19:01 Number of views : 2,070

12c90adc5245a32d84978bcac061323b_1616839633_216.png
 


The head of a leading South Korean genetic research company said at a global medical forum "Dementia Forum X" (DFx) that dementia will become controllable by early detection and treatment.

Eone Diagnomics Genome Center's (EDGC) co-CEO Lee Min-seob participated in the event from Nov. 25 to 27 as a keynote speaker at the COEX in Seoul's Gangnam District

"While dementia is considered one of the most feared diseases as the global population is aging with longer life expectancies, it is also a disease that needs customized preemptive treatment following a precise prognosis," said Lee at the DFx. 


"That will become possible with EDGC's artificial intelligence-based state-of-the-art algorithm that can analyze an individual's genome and other clinical data."

EDGC said DFx is one of the world's three most well-known forums on the disease.

In 2019, EDGC won a 9 billion won ($8.14 million) three-year state project that allowed the Songdo-based firm in Incheon to study and find ways of predictively diagnosing and preventing dementia and mild cognitive impairment.

As part of the project, the company is developing an early-detection kit, a multi-dimensional predictive diagnostic system, and new treatment drugs for the disease.

No posts found.